CAR-T cells have been recently approved by numerous international drug agencies for the treatment of haematological malignancies with tremendous results. However, there is a lack of diversity of tumour-associated antigens with these CAR-T cell products. Identification and characterization of novel tumour antigens is required to expand tumour antigen repertoire that can be used with CAR-T or engineered TCR T cells into new malignancies, including solid tumours.
The focus of this On Demand Webinar is on new ultra-high content and 3D imaging technologies that enable you to rapidly and precisely identify and characterize novel tumour antigens. These novel tumour antigens can be used to discover new targets for CAR-T or engineered TCR T cells products.
Watch this On Demand with Dr Olaf Hardt, Manager R&D, Miltenyi Biotec GmbH and Dr Uwe Schröer, Senior Product Manager, LaVision BioTec GmbH, as they discuss: